- Baxter’s fourth-quarter sales from continuing operations were $2.75 billion, surpassing the estimate of $2.67 billion.
- Pharmaceutical sales reached $643 million, exceeding the anticipated $636.7 million.
- The company’s adjusted earnings per share (EPS) from continuing operations were 58 cents, above the estimated 52 cents.
- Baxter’s Research and Development (R&D) expenses amounted to $211 million.
- Analyst recommendations include 4 buys, 10 holds, and 2 sells.
A look at Baxter International Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Baxter International has a positive long-term outlook. With a dividend score of 4, the company demonstrates a strong ability to provide consistent returns to shareholders. Additionally, its value score of 3 indicates a solid valuation relative to its peers, which could be attractive to investors seeking a stable investment.
However, Baxter International scored lower in growth and resilience, with scores of 2 for both factors. This suggests that the company may face challenges in terms of expanding its business and weathering potential economic downturns. Despite this, with a momentum score of 3, there might be some positive market sentiment surrounding the company’s stock in the near term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
